Inhibitory effect and mechanism of platycodin D combined with imatinib on K562/R.
10.19540/j.cnki.cjcmm.20171027.012
- Author:
Qun DAI
1
;
Yu-Qing GE
1
Author Information
1. First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.
- Publication Type:Journal Article
- Keywords:
Bcr/abl fusion gene;
K562/R;
PI3K/AKT/mTOR signal pathway;
imatinib;
platycodin D
- MeSH:
Antineoplastic Agents;
pharmacology;
Apoptosis;
Cell Proliferation;
Drug Resistance, Neoplasm;
Humans;
Imatinib Mesylate;
pharmacology;
K562 Cells;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
pathology;
Saponins;
pharmacology;
Signal Transduction;
Triterpenes;
pharmacology
- From:
China Journal of Chinese Materia Medica
2018;43(2):385-389
- CountryChina
- Language:Chinese
-
Abstract:
Platycodin D(PD) has a significantly inhibitory effect on multiple malignant tumors, and can inhibit the proliferation of leukemia cells K562 and induce apoptosis. However, its effect in improving the sensitivity of drug-resistant cells to imatinib and their molecular mechanism remained unclear. To investigate the effect and mechanism of PD alone or combined with imatinib (IM) in inhibiting CML imatinib resistant cell line K562/R, the cell proliferation was examined by CCK8 assay to reveal the effect of PD on the inhibitory function of imatinib. Cell apoptosis was detected by Annexin V-FITC/PI double staining. Protein expressions of cleaved caspase-3, cleaved caspase-9, PARP, cleaved PARP, Bcr/abl, p-AKT and p-mTOR were detected by Western blot. The results showed that the inhibitory effect of PD combined with imatinib on the proliferation and apoptosis of K562/R cells was significantly higher than that of the control group and the single drug group. Protein expressions of cleaved caspase-3, cleaved caspase-9 and cleaved PARP were significantly up-regulated in the combination group, and protein expressions of PARP, Bcr/abl, p-AKT and p-mTOR were down-regulated. The results indicated that PD increased the sensitivity of drug-resistant cells to imatinib, and the inhibitory effect of PD combined with imatinib was significantly better than the single drug on cell proliferation, induction of apoptosis, inhibition of Bcr/abl protein and PI3K/AKT/mTOR signaling pathway.
